Zoetis (ZTS) : The highest level Zoetis (ZTS) is projected to reach is $62 for the short term and the lowest estimate is at $49. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $54.43 and the possibility the share price can swing is $5.5.
Zoetis (ZTS) : 9 analysts are covering Zoetis (ZTS) and their average rating on the stock is 1.67, which is read as a Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Barclays maintains their rating on the shares of Zoetis (NYSE:ZTS). The current rating of the shares is Equal-weight. Equity Analysts at the Firm raises the price target to $49 per share from $45 per share. The rating by the firm was issued on August 4, 2016.
Zoetis (NYSE:ZTS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $51.15 and $50.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $51.15. The buying momentum continued till the end and the stock did not give up its gains. It closed at $51.11, notching a gain of 0.02% for the day. The total traded volume was 2,695,047 . The stock had closed at $51.10 on the previous day.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.